Intellia Therapeutics (NTLA) Liabilities and Shareholders Equity (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Liabilities and Shareholders Equity data on file, last reported at $758.8 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $758.8 million, down 23.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.4 billion (down 24.59% YoY), and the FY2025 annual result was $842.1 million, down 29.29% from the prior year.
• Liabilities and Shareholders Equity retreated to $758.8 million in Q1 2026 per NTLA's latest filing, from $842.1 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $1.5 billion in Q4 2022 and troughed at $758.8 million in Q1 2026.
• A 5-year average of $1.1 billion and a median of $1.2 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity jumped 67.78% in 2022, then declined 29.29% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.5 billion in 2022, then slipped by 14.42% to $1.3 billion in 2023, then dropped by 8.45% to $1.2 billion in 2024, then decreased by 29.29% to $842.1 million in 2025, then retreated by 9.9% to $758.8 million in 2026.
• Business Quant data shows NTLA's Liabilities and Shareholders Equity at $758.8 million in Q1 2026, $842.1 million in Q4 2025, and $925.3 million in Q3 2025.